Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial

20260 citationsJournal Articlegold Open Access

Authors

Clinicaltrials.gov NCT04560569, Sep 23, 2020.

Good health and well-being

Published in: BMC Infectious Diseases

Field-Weighted Citation Impact: 0.00